OncoMatch/Clinical Trials/NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Is NCT07225946 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Pasritamig and Docetaxel for prostatic neoplasms, castration-resistant.
Treatment: Pasritamig · Docetaxel · Prednisone — The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen receptor pathway inhibitor
Cannot have received: cytotoxic chemotherapy
Cannot have received: klk-2 directed therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arkansas Urology · Little Rock, Arkansas
- Valkyrie Clinical Trials · Los Angeles, California
- Kaiser Permanente Southern California · Riverside, California
- Grand Valley Oncology · Grand Junction, Colorado
- Colorado Clinical Research · Lakewood, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify